Favezelimab联合帕博利珠单抗治疗抗PD-1初治复发/难治经典型霍奇金淋巴瘤的1/2期研究
MK-4280-003研究评估Favezelimab联合帕博利珠单抗治疗复发/难治血液肿瘤,本文报告抗PD-1初治经典型霍奇金淋巴瘤队列结果。安全导入期确定RP2D为Favezelimab 800 mg联合帕博利珠单抗200 mg每3周静脉给药,扩展期队列1纳入30例,客观缓解率83%,完全缓解率37%,安全性可控。
要点
- RP2D为Favezelimab 800 mg联合帕博利珠单抗200 mg每3周静脉给药。
- 抗PD-1初治R/R cHL患者ORR达83%,CR率37%。
- 中位PFS 19.4个月,24个月OS率93%,安全性可控。
核心结论
- Favezelimab联合帕博利珠单抗在抗PD-1初治复发/难治经典型霍奇金淋巴瘤中显示抗肿瘤活性和可控的安全性。
研究设计与样本
- 1/2期MK-4280-003研究包含安全导入期(4个队列)确定RP2D和疗效扩展期,队列1纳入30例抗PD-1初治R/R cHL成人患者。
主要发现
- 治疗相关不良事件发生27例(90%),3或4级7例(23%),无5级,5例(17%)因不良事件停药。
- 客观缓解率83%(95% CI,65-94),完全缓解率37%(95% CI,20-56)。
- 中位缓解持续时间17.0个月(范围2.6-33.3+),估计44%的缓解者在≥24个月时仍有缓解。
- 中位无进展生存期19.4个月(95% CI,9.5-28.5),24个月无进展生存率46%。
- 中位总生存期未达到(NR;95% CI,46.9-NR),24个月总生存率93%。
关键数值与推荐
- RP2D为Favezelimab 800 mg联合帕博利珠单抗200 mg每3周静脉给药。
- 安全导入期21例中1例发生剂量限制性毒性(4级自身免疫性肝炎)。
临床怎么用
- 对于抗PD-1初治的复发/难治经典型霍奇金淋巴瘤患者,Favezelimab联合帕博利珠单抗可作为候选治疗方案,需关注免疫相关不良事件。
局限性
- 队列1样本量较小(30例),结果需更大规模研究验证。
- 中位总生存期未达到,长期生存获益需更长时间随访。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The phase 1/2 MK-4280-003 study evaluated favezelimab plus pembrolizumab for relapsed or refractory (R/R) hematologic malignancies. We report results in anti-PD-1-naive R/R classical Hodgkin lymphoma (cHL; cohort 1). The study comprised a safety lead-in (across 4 cohorts) to establish the recommended phase 2 dose (RP2D) of favezelimab plus pembrolizumab and an efficacy expansion phase (pembrolizumab 200 mg plus favezelimab at RP2D intravenously [IV] every 3 weeks [Q3W]). Adults with anti-PD-1-naive R/R cHL were enrolled in cohort 1. Primary end point was safety (dose-limiting toxicity [DLT], adverse events [AEs], and AEs leading to discontinuation) to establish RP2D. Objective response rate (ORR) was secondary. Duration of response (DOR), progression-free survival (PFS), and overall survival (OS) were exploratory. RP2D was favezelimab 800 mg plus pembrolizumab 200 mg IV Q3W. DLT occurred in 1 of 21 participants in the safety lead-in (grade 4 autoimmune hepatitis). Cohort 1 enrolled 30 participants. Treatment-related AEs occurred in 27 participants (90%; grade 3 or 4 in 7 participants [23%]; no grade 5), and 5 participants (17%) discontinued treatment. ORR was 83% (95% CI, 65-94); complete response rate was 37% (95% CI, 20-56). Median DOR was 17.0 months (range, 2.6-33.3+); an estimated 44% of responders continued to have responses after ≥24 months. Median PFS was 19.4 months (95% CI, 9.5-28.5); 24-month PFS rate was 46%. Median OS was not reached (NR; 95% CI, 46.9-NR); 24-month OS rate was 93%. Favezelimab plus pembrolizumab showed antitumor activity and manageable safety in participants with anti-PD-1-naive R/R cHL. This trial was registered at www.ClinicalTrials.gov as NCT03598608.
引用
- Johnson NA, Lavie D, Borchmann P, et al. Phase 1/2 study of favezelimab plus pembrolizumab in anti-PD-1-naive relapsed or refractory classical Hodgkin lymphoma. Blood Adv. 2026. PMID: 42826707. doi:10.1182/bloodadvances.2025018506
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。